Psoriasis is an independent predictor of increased risk of allergic reaction during percutaneous coronary interventions. Big data analysis from the Polish National PCI Registry (ORPKI)
Abstract
Background: The presence of psoriasis is currently considered by the European Society of Cardiology cardiovascular prevention guidelines of 2016 as one possible cardiovascular risk factor. Patients with psoriasis and concomitant coronary artery disease treated by means of percutaneous coronary intervention (PCI) are a fairly large subgroup of patients that have been usually omitted in mainstream research. The aim herein, was to identify the incidence of psoriasis, baseline characteristics and periprocedural outcome with a special focus on procedural complications in patients undergoing percutaneous coronary procedures.
Methods: All consecutive patients who had either coronary angiography or coronary angiography with immediate PCI in Poland in 2014 and 2015 were included. Patients were assigned to two groups based on previous diagnosis: with psoriasis and without psoriasis. Clinical outcome was defined as any periprocedural death.
Results: There were 405,078 patients included in this analysis. Psoriasis (moderate or severe) was diagnosed in 1507 (0.4%) of them. Psoriasis was an independent predictor of allergic reaction occurrence (odds ratio [OR] 6.02; 95% confidence interval [CI] 1.44–25.22; p = 0.014). After propensity score adjustment, psoriasis remained a significant predictor of allergic reaction (OR 5, 95% CI 1.2–20.7; p = 0.0245). There were no differences in rates of periprocedural deaths in patients with or without psoriasis (death: 0.95% vs. 0.62%, p > 0.05).
Conclusions: Severe or moderate psoriasis is an independent risk factor for the occurrence of allergic reaction during percutaneous coronary procedures. There were no differences in periprocedural mortality and complications in patients with versus those without psoriasis.
Keywords: infarctioncoronarypsoriasisanaphylaxis
References
- Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol. 2011; 131(5): 1007–1010.
- Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol. 2008; 159 Suppl 2: 2–9.
- Schäfer T. Epidemiology of psoriasis. Review and the German perspective. Dermatology. 2006; 212(4): 327–337.
- Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006; 6(7): 508–519.
- Kremers HM, McEvoy MT, Dann FJ, et al. Heart disease in psoriasis. J Am Acad Dermatol. 2007; 57(2): 347–354.
- Piepoli M, Hoes A, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016; 252: 207–274.
- Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008; 58(6): 1031–1042.
- Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012; 60: 645–681.
- El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venereol. 2010; 24(6): 661–666.
- Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007; 156(2): 271–276.
- Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015; 74(2): 326–332.
- Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013; 27 Suppl 3: 12–29.
- Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013; 2(2): e000062.
- Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study. J Invest Dermatol. 2013; 133(10): 2347–2354.
- Ahlehoff O, Lindhardsen J, Gislason GH, et al. Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries. BMC Cardiovasc Disord. 2012; 12: 79.
- Egeberg A, Thyssen JP, Jensen P, et al. Risk of myocardial infarction in patients with psoriasis and psoriatic arthritis: a nationwide cohort study. Acta Derm Venereol. 2017; 97(7): 819–824.
- Ochała A, Siudak Z, Legutko J, et al. Percutaneous interventions in cardiology in Poland in the year 2014. Summary report of the Association of Cardiovascular Interventions of the Polish Cardiac Society AISN PTK. Postepy Kardiol Interwencyjnej. 2015; 11(3): 177–181.
- Siudak Z, Tokarek T, Dziewierz A, et al. Reduced periprocedural mortality and bleeding rates of radial approach in ST-segment elevation myocardial infarction. Propensity score analysis of data from the ORPKI Polish National Registry. EuroIntervention. 2017; 13(7): 843–850.
- Bendel R, Afifi AA. Comparison of stopping rules in forward “stepwise” regression. J Am Stat Ass. 1977; 72(357): 46–53.
- Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989; 129(1): 125–137.
- Tomz M, King G, Zeng L. ReLogit: rare Events Logistic Regression. J Statistical Software. 2003; 8: 1–27.
- Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013; 68(4): 654–662.
- Lerman JB, Joshi AA, Chaturvedi A, et al. Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study. Circulation. 2017; 136(3): 263–276.
- Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009; 129(10): 2411–2418.
- Schiano P, Steg PG, Barbou F, et al. A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. Eur Heart J Acute Cardiovasc Care. 2012; 1(1): 75–78.
- Gollapudi RR, Teirstein PS, Stevenson DD, et al. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004; 292(24): 3017–3023.
- Juergens CP, Khaing AMi, McIntyre GJ, et al. Adverse reactions of low osmolar non-ionic and ionic contrast media when used together or separately during percutaneous coronary intervention. Heart Lung Circ. 2005; 14(3): 172–177.
- Hofmeier KS. Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs. Allergo J Int. 2015; 24(2): 58–66.
- Montone RA, Sabato V, Sgueglia GA, et al. Inflammatory mechanisms of adverse reactions to drug-eluting stents. Curr Vasc Pharmacol. 2013; 11(4): 392–398.
- Kogias JS, Papadakis EX, Tsatiris CG, et al. Kounis syndrome: a manifestation of drug-eluting stent thrombosis associated with allergic reaction to contrast material. Int J Cardiol. 2010; 139(2): 206–209.
